Nexalin Technology, Inc. (NXL) Stock Analysis

Company Overview

The market values Nexalin Technology, Inc. (NXL) at $4.20M. The company sits in the Healthcare sector, in the Medical Devices industry. The company reports 8 employees.

The 52-week range on file runs from $4.75 to $60.00. The most recent close on file for NXL is $5.06, dated September 4, 2026. That is −$0.30 (−5.60%) against the previous close. The latest close sits 6.62% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $301.65K. That is +78.78% against the prior fiscal year, when revenue was $168.72K. The same year closed with a net loss of $8.22M. Profit margin runs at 0%. That is 1.7 percentage points above the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −13.8.

Across the 4 fiscal years on file, revenue moves from $1.32M in 2022 to $301.65K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 19.33 times revenue. On price-to-sales that is 6.5 times the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +495.29%. Across 3 years the annualized return works out at +132.81%. Beta against the wider market is reported at 3.98. Annualized volatility over the trailing 4 years is 1,439%.

Growth & Income

The record shows no dividend for NXL.

So far in 2026 the price is +806.81%. The strongest complete calendar year on file is 2024 at +581.48%; the weakest is 2025 at −79.78%. Of the 3 complete calendar years on file, 1 finished higher.